Articles

Podcasts

Videos

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Travel issues related to COVID-19 were responsible for the delay in the approval of the Biologics License Application.

FDA Delays Approval of Bimekizumab for Plaque Psoriasis

Data from the PAUSE clinical trial reveals that more participants experienced psoriasis relapse in the abatacept group than the ustekinumab group.

Abatacept Ineffective in Prevention of Psoriasis Relapse

A recent press release detailed the phase 3 findings that were presented at the virtual conference, which shows that bimekizumab was well-tolerated and efficacious in patients with moderate to severe plaque psoriasis.

Promising Bimekizumab Data Presented at EADV

The treatment was approved for adult patients with plaque psoriasis in 2018.

FDA Approves Halobetasol Propionate for Adolescent Plaque Psoriasis

Though the severity of the COVID-19 virus did not differ in participants with different dermatological conditions, their conditions were affected in alternate ways.

COVID-19 Linked to Exacerbations in Skin Diseases

A rarity in biologic treatments for patients with moderate-to-severe plaque psoriasis, Dr. Miller notes that patients treated with guselkumab recorded overwhelmingly positive PASI scores.

Lloyd Miller, MD, PhD: Guselkumab Shows Great Efficacy Across all Psoriasis Populations

The prevalence of striae distensae was notably higher in psoriasis than atopic dermatitis.

Study Analyzes Topical Glucocorticoid-Related Skin Atrophy in Atopic Dermatitis

An ongoing study of the IL-17A and IL-17F inhibitor showed patients with moderate to severe plaque psoriasis achieved long-term skin clearance results.

Trial Suggests Bimekizumab Effective in Clear Skin Management

More research is needed to understand the pathogenesis underlying this association. 

Psoriasis Associated with Increased Risk for Retinal Diseases

A higher proportion of patients with immune-mediated diseases experienced ≥1 thromboembolic events at baseline compared to those without an IMD.


Immune-Mediated Diseases May Increase Risk for Thromboembolic Events

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.